Insufficient duration of sleep is a highly prevalent behavioral pattern in society that has been shown to cause an increase in spontaneous pain and sensitivity to noxious stimuli. Prostaglandins (PGs), in particular PGE2, are key mediators of inflammation and pain, and we investigated whether PGE2 is a potential mediator in sleep-loss-induced changes in nociceptive processing. Twenty-four participants (7 females, age 35.1 ± 7.1 years) stayed for 7 days in the Clinical Research Center. After two baseline days, participants were randomly assigned to either 3 days of 88 h of sleep deprivation (TSD, N = 15) or 8 h of sleep per night (N = 9), followed by a night of recovery sleep. Participants rated the intensity of various painrelated symptoms every 2 h across waking periods on computerized visual analog scales. PGE2 was measured in 24-h-urine collections during baseline and third sleep deprivation day. Spontaneous pain, including headache, muscle pain, stomach pain, generalized body pain, and physical discomfort significantly increased by 5-14 units on a 100-unit scale during TSD, compared to the sleep condition. Urinary PGE2 metabolite significantly increased by about 30% in TSD over sleep condition. TSD-induced increase in spontaneous pain, in particular headache and muscle pain, was significantly correlated with increase in PGE2 metabolite. Activation of the PGE2 system appears to be a potential mediator of increased spontaneous pain in response to insufficient sleep. Ó
Introduction
Experimental evidence has accumulated over the past 30 years supporting a reciprocal relationship between sleep and pain: while the experience of pain can disrupt sleep [19] , experimental sleep loss itself has been shown to cause changes in the nociceptive system neuroplasticity in animals and humans, such as hyperalgesia and the development of spontaneous pain, including muscle pain, headache, and back pain [13, 30] .
Despite the well-established link between sleep and pain, there is surprisingly very little knowledge about the underlying mechanisms that interface sleep and pain. However, this knowledge is essential for the development of interventions that would mitigate the sleep-pain interaction, and improve physical well-being in those undergoing periods of insufficient sleep, such as patients suffering from chronic pain, health care workers performing or serving on-call duty, military personnel, parents attending to infants and toddlers, time zone travellers, shift workers, among others.
Activation of inflammatory components is a central feature in various types of painful conditions, a finding frequently reported under conditions of experimental sleep loss. Partial and acute sleep deprivation in healthy volunteers have been shown to increase proinflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, its soluble receptor p55, and C-reactive protein (CRP) [8, 18, 29, 35, 36] . Little is known about the effects of sleep loss on the prostaglandin system, though it plays a significant role in sleep-wake regulation in animals [9] , and is well studied for its involvement in the origin of inflammatory pain [7] .
Prostaglandins (PGs) are synthesized from membrane-released arachidonic acid when cells are activated by mechanical trauma, or by contact with cytokines, growth factors, and other inflammatory processes [6] . Cyclooxygenases (COX) catalyse the conversion of arachidonic acid to unstable PGH2, which then is converted to the functionally important prostanoids PGD2, E2, F2, I2, and thromoboxane by specific synthases. PGs can be synthesised by virtually every cell of the body, including macrophages and endothelial cells.
PGE2 appears to be a principal mediator of inflammation and promotes the development of inflammatory signs, including pain. At a peripheral level, PGE2 is able to sensitize the nociceptive system through binding to EP receptors located on peripheral terminals of primary sensory neurons, resulting in an increased sensitivity to noxious stimuli (i.e. hyperalgesia). On a central level, numerous studies have shown that PGE2 is able to change neuronal excitability and synaptic dis-inhibition in the spinal cord [34] 
